Skip to main navigation Skip to search Skip to main content

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer

  • Nicholas C. Turner
  • , Mafalda Oliveira
  • , Sacha J. Howell
  • , Florence Dalenc
  • , Javier Cortes
  • , Henry L. Gomez Moreno
  • , Xichun Hu
  • , Komal Jhaveri
  • , Petr Krivorotko
  • , Sibylle Loibl
  • , Serafin Morales Murillo
  • , Meena Okera
  • , Yeon Hee Park
  • , Joohyuk Sohn
  • , Masakazu Toi
  • , Eriko Tokunaga
  • , Samih Yousef
  • , Lyudmila Zhukova
  • , Elza C. De Bruin
  • , Lynda Grinsted
  • Gaia Schiavon, Andrew Foxley, Hope S. Rugo
  • Royal Marsden NHS Foundation Trust
  • Vall d’Hebron University Hospital
  • Vall d'Hebron Institute of Oncology
  • The Christie NHS Foundation Trust
  • Institut Claudius Regaud
  • Pangaea Oncology IBCC
  • Universidad Europea
  • Universidad Ricardo Palma
  • Fudan University
  • Cornell University
  • Russian Ministry of Health
  • GBG Forschungs GmbH
  • Bethanien
  • Institute for Research in Biomedicine
  • Icon Cancer Centre
  • Yonsei University
  • Kyoto University
  • National Hospital Organization Kyushu Cancer Center
  • Emek Medical Center
  • Loginov Moscow Clinical Scientific Center
  • AstraZeneca
  • University of California at San Francisco

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science